Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 9/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 7/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6239207 | 0.92 | GRIA4 (0.44) | GRIA4GRIA2CXCR2NPY5RCYP2C19 | |
| SCHEMBL6240181 | 0.85 | GRIA4 (0.45) | GRIA4GRIA2NPY5RCYP2C19 | |
| SCHEMBL6240540 | 0.81 | ADAM17 (0.41) | GRIA4GRIA2 | |
| SCHEMBL6240616 | 0.78 | CYP11B1 (0.38) | GRIA4NPY5R | |
| SCHEMBL6242243 | 0.78 | CXCR2 (0.37) | GRIA4GRIA2CXCR2 | |
| SCHEMBL6243805 | 0.78 | GRIA4 (0.44) | GRIA4GRIA2 | |
| SCHEMBL6241425 | 0.78 | GRIA4 (0.48) | GRIA4GRIA2CXCR2 | |
| SCHEMBL6240728 | 0.75 | GRIA4 (0.39) | GRIA4GRIA2 | |
| SCHEMBL6242831 | 0.74 | GRIA2 (0.52) | GRIA4GRIA2 | |
| SCHEMBL6245808 | 0.74 | CA12 (0.41) | GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395550-B1 | CYCLOALKENYLSULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2005-06-29 | — | — | EP | claimed |
| US-20040157817-A1 | Cycloalkenylsulfonamide derivatives | CANTELL BUDDY EUGENE (US) | 2004-08-12 | — | — | US | claimed |
| EP-1395550-A1 | CYCLOALKENYLSULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2004-03-10 | — | — | EP | claimed |
| WO-2002098847-A1 | CYCLOALKENYLSULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-12-12 | — | — | WO | claimed |
| EP-1395550-B1 | CYCLOALKENYLSULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040157817-A1 | Cycloalkenylsulfonamide derivatives | CANTELL BUDDY EUGENE (US) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157817-A1 | Cycloalkenylsulfonamide derivatives | GRIN2B, GRIN2A, GRIN1 | GRIA4 14/4885GRIA2 7/4885CXCR2 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.